Rastogi et al. demonstrated that treatment of two established breast cancer cell lines, MCF7 and T47D, with anti-GLUT1 antibody in vitro caused up to a 75% reduction in proliferation [52]. The gene discussed is SLC2A1; the disease is breast carcinoma.